DexCom, Inc. is on the Cruelty Free Investing use of animals list because they conduct pre-clinical studies of some drugs on animals to assess a product’s safety profile.
The following document cites that the company conducts preclinical trials on animals.
“Data not related to physiologic sensor testing, such as tissue biocompatability, tissue toxicity testing, short or long-term animal testing, tissue-[*****]® material peel testing, histology, bacterial bioburden of [*****] parts, which is obtained as part of DexCom’s regulatory and developmental processes, will be provided to SMTLLC visually and verbally, as it becomes available.” (Page 11) Read the full document.
DexCom, Inc. is a medical device manufacturing company. The company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients. Its products include Dexcom G4 PLATINUM System, Dexcom studio and Mobile apps. The company was founded by John F. Burd in May 1999 and is headquartered in San Diego, CA. [Source: MarketWatch]
Company Website: http://www.dexcom.com